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Abstract
Dilated cardiomyopathy (DMC) of ischemic or non-ischemic aetiology remains a lethal 
condition nowadays. Despite early percutaneous or medical revascularization after an 
acute myocardial infarct (AMI), many patients still develop DMC and severe heart fail-
ure due to cardiac remodelling. Possibility of regenerating myocardium already dam-
aged or at least inducing a more positive cardiac remodelling with use of biodegradable 
scaffolds has been attempted in many experimental studies, which can be cellular or 
acellular. In the cellular scaffolds, the cells are incorporated in the structure prior to 
implantation of the same into the injured tissue. Acellular scaffolds, in turn, are compos-
ites that use one or more biomaterials present in the extracellular matrix (ECM), such as 
proteoglycans non-proteoglycan polysaccharide, proteins and glycoproteins to stimu-
late the chemotaxis of cellular/molecular complexes as growth factors to initiate specific 
regeneration. For the development of scaffold, the choice of biomaterials to be used must 
meet specific biological, chemical and architectural requirements like ECM of the tissue 
of interest. In acute myocardial infarction, treating the root of the problem by repair-
ing injured tissue is more beneficial to the patient. Inducing more constructive forms of 
endogenous repair. Thus, patches of acellular scaffolds capable of mimicking the epicar-
dium and ECM should be able to attenuate both cardiac remodelling and adverse cardiac 
dysfunction.
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1. Introduction
Cardiomyopathy was originally defined as heart muscle disease of unknown cause, and was dis-
tinguished from other disease caused by a specific aetiology, such as ischemic heart disease. It is 
well known that cardiovascular disease is a main cause of morbidity and mortality worldwide, 
and many lives are lost due to heart attack. The understanding of cardiomyopathies in both 
the public and medical communities has been impaired by persistent confusion surrounding 
definitions and nomenclature. Generally, the cardiomyopathies are associated with mechanical 
or electrical dysfunction that exhibit inappropriate ventricular hypertrophy or dilatation [1, 2].
Many definitions of heart failure (HF) have been put forward over last 60 years or more. These 
highlight one or several features of this complex syndrome such as hemodynamic, oxygen 
consummation and exercise capacity [3]. HF is characterized by breathlessness, ankle swell-
ing and fatigue that may be accompanied by elevated jugular venous pressure, pulmonary 
crackles and peripheral oedema caused by a structural and/or functional cardiac abnormal-
ity, resulting in a reduced cardiac output and/or elevated intra-cardiac pressures at rest or 
during stress [4]. The cell loss in the myocardium leads to dilation of ventricular wall and 
remodelling of the heart and, eventually, to congestive HF [5]. New-onset HF may also pres-
ent acutely, for example, as a consequence of acute myocardial infarction (AMI), or sub-acute 
in a way, in patients with a dilated cardiomyopathy (DCM). The history is key in making the 
diagnosis of HF, grading symptom severity and not only establishing the underlying cause 
but also identifying factors that may have precipitated decompensation [6, 7].
DCM is the most common cardiomyopathy and has many causes. In the absence of abnormal 
loading condition and severe coronary artery disease, the DCM is characterized by abnormal 
findings of chamber size and wall thickness, left ventricular dilation and impaired contraction 
of the left or both ventricles [8]. This reorganization results in abnormal levels of resting ten-
sion with activation of the cell death pathway and a further reduction in myocardial perfor-
mance thus establishing a vicious feedback loop [9, 10]. The DCM ischemic or non-ischemic 
aetiology remains a lethal condition and the most common indication for heart transplanta-
tion. This disorder occurs mostly in adults and for 60% of childhood cardiomyopathies, with 
infants younger than 12 months having the highest incidence [11]. Although genetic causes 
are important at all ages of primary cardiomyopathies, the DCM is predominantly of acquired 
cause. However, familial disease with a genetic origin has been reported in a minority of cases 
[1]. The DCM phenotype with sporadic occurrence may derive from a broad range of primary 
and secondary causes, including infectious agents and parasitic. Other causes include toxins, 
chronic excessive consumption of alcohol, chemotherapeutics agents, autoimmune disorders, 
collagen vascular disorders, neuromuscular disorders caused by mutations in the structural 
protein dystrophin [12, 13], muscular dystrophy caused by mutations in the nuclear mem-
brane proteins, lamin A/lamin C rate, metabolic, endocrine and nutritional disorders [14].
DCM is a mixture of primary cardiomyopathies acquired (no genetic) and genetic causes, and it 
is related to left ventricle (LV) dysfunction. Following myocardial infarction (MI), the LV under-
goes a series of cardiac wound healing responses that involve stimulation of robust inflamma-
tion to clear necrotic myocytes and tissue debris and induction of extracellular matrix (ECM) 
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protein synthesis to generate a scar. The LV is a complex mixture of cell types, including car-
diomyocytes, fibroblasts, immune cells, endothelial and vascular smooth muscle cells, as well 
as ECM that surrounds these cell types. Cell death was less studied, and whether myocyte cell 
loss participated in the initiation and evolution of heart failure remains to be established [10].
The cardiac fibrosis is the main event after myocardial infarction, which is characterized by 
deposition in the infarcted area, with a consequent increases of stiffness, the contraction as relax-
ation behaviour of the heart are affects resulting in a decrease in cardiac function. The continu-
ous increase of cardiac fibrosis leads to a progressive decrease in heart tissue contractility and 
heart failure [15–17]. No efficient therapies that can inhibit cardiac fibrosis from progressing in 
the infarcted hearts to preserve cardiac function and prevent heart failure are available.
Myofibroblasts are widely accepted to be responsible for cardiac fibrosis. Thus, rationally 
designed anti-fibrotic therapies are likely to be invaluable in curbing this health problem. 
However, there is no therapy for fibrotic disease in general largely because the underlying basis 
of fibrosis is unclear, but may result from growth factor-mediated differentiation of resident 
mesenchymal cells or recruitment of microvascular pericytes-like progenitor cells [18]. The myo-
fibroblasts also express highly contractile protein smooth muscle actin (α-SMA) that remodels 
the surrounding ECM because they are connected to ECM trough specialized cell surface struc-
tures called focal adhesion. In the context of the heart, excessive scarring can cause increases in 
tissue stiffness, cardiomyocyte atrophy, arrhythmia and hypoxia. Abundant data suggest that 
a complex interaction involving TGF-β (transforming growth factor β), ET-1 (endothelin-1), 
Ang-II (angiotensin II) and PDGF (platelet-derived growth factor) causes fibrogenesis [19–21].
2. Cardiac repair
The adult mammalian heart has negligible regenerative capacity, and thus, normal cardiac 
repair, for example, post infarction, is dependent on the clearance of dead cells and on the for-
mation of a scar tissue to help preserve heart integrity. Myofibroblast is of mesenchymal origin, 
it has a key role in cardiac fibrogenesis, and after heart attack, it promotes connective tissue 
remodelling. Myofibroblasts contract fibroblasts that express α-smooth muscle actin (αSMA) to 
facilitate wound closure [22]. Different approaches have been explored to treat cardiac fibrosis, 
such as systemic delivery of anti-fibrotic drugs, localized transplantation of biomaterials, local-
ized delivery of antibiotic drugs using biomaterials and localized delivery of cells. Localized 
transplantation of biomaterials controls cardiac fibrosis by decreasing left ventricular wall 
stress to decrease the elevated wall stress-induced inflammation. Selection of biomaterials with 
suitable mechanical properties is critical to decrease wall stress. The ideal biomaterials with 
suitable physical, chemistry and physio-mechanical properties are critical to decrease wall 
stress. It should have elasticity and stiffness matching those of the heart tissue. The biodegra-
dation of this material should occur slowly from 6 to 8 weeks and simultaneously the cells from 
surrounding tissue may penetrate into the infarcted area for attenuation of cardiac fibrosis.
Many people survive myocardial infarction. If help happens quickly, treatment can limit dam-
age to your heart muscle, less heart damage improves your chances for a better quality of life 
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after a myocardial infarction, but a delay of 2 hours or more after symptoms start can result 
in lasting heart damage or death. However, medical follow up as lifestyle changes, medi-
cines to control chest pain or discomfort and anticlotting medicines will help prevent another 
heart attack, but this will not rehabilitate cardiac function. Additionally, the biomaterial may 
provide adequate mechanical support to prevent tissue rupture, and high efficacy can be 
achieved to prevent new myofibroblast formation and ECM synthesis especially collagen.
3. Tissue regeneration
Therapeutic potential of heart transplant is limited by very small numbers of donor hearts 
available relative to the need and is complicated by long-term allograft vasculopathy. 
Interventional cardiology for acute MI has yielded significant advances over the past two 
decades, while there is still a considerable number of patients who either arrive too late to 
the clinics or are resistant to angioplasty. Localized drug delivery, yet the widespread clinical 
application of current approaches, is obstructed by the low therapeutic efficacy. Development 
of new and translational delivery approaches to improve therapeutic efficacy is essential to 
push the anti-cardiac fibrosis therapy towards clinical applications.
The human body is a complex system and has very large surface area in which multitude of 
cell-based interactions contribute to the viability and function of its parts. Complexity is obvi-
ously creating an environment that favours the interactions between a cell for sharing and 
propagation of important information exchange, often leading to complex and every detail 
very carefully planned from a target issue or cell [23]. Classic examples of such cell-based 
information exchange in the body include as just a few examples [24] as satellite cells (myo-
blasts), cardiomyocytes and cardiac pacemaker cells.
The heart possesses regenerative capacity attributed to endogenous and exogenous progeni-
tor cell populations [25]. Thus, there is a growing interest in developing new approaches to 
treat MI, cardiovascular tissue engineering is currently considered as a promising alternative 
therapy to restore the structure and function of infarcted adult myocardium via application 
of a biological device, onto the ischemic tissue [26].
Cellular cardiomyoplasty is considered a novel therapy, in which stem cells are used for car-
diac repair. Stem cells are potential therapeutic approach that could be the ultimate solution 
for salvaging damaged cardiomyocyte. However, more evidence is needed to widely advance 
the use of this modality. The concentration of stem cells, dose-effect relationship and safety 
of therapy need to be further investigated. One particular topic in regard to stem cell safety is 
the tumorigenicities of embryonic stem cells [27].
Unlike heart valves or blood vessels, heart muscle has no replacement alternatives. Evidence 
suggest that stem-cell-based cardiac therapy has centred on the premise that functional myo-
cardium may be restored by transplanting cardiovascular cells derived from exogenous stem 
cells into injured hearts [28, 29]. Recent advances in methods of stem cell isolation and culture 
in bioreactors, the synthesis of bioactive materials and the use of proteomics to better under-
stand matrix metalloproteinase role in post myocardium infarction LV remodelling show 
promise to contribute to creation of engineered cardiac tissue in vitro [30–32].
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New discoveries in stem cell biology suggest that stem cells are a potential source of heart 
muscle cells and blood vessels and can be used by clinicians to rebuild or replace damaged 
heart tissue [18]. The ideal clinical intervention would either avoid such scar formation, 
or simply replace formed scar tissue with functioning cardiac muscle tissue [33]. In a first 
approach to such therapy, investigators have used injections of new cells into damaged 
areas of cardiac tissue [34]. These studies have met with limited success due to cell death, 
exit of cells from the heart, and poor cellular integration with the receiving heart tissue [29, 
35]. However, multiple attempts have been made at injecting stem cells into myocardial 
tissue and injection of bone marrow cells after acute MI has even been tested in various 
clinical studies [27].
The possibility that adult stem cells can repair infarcted myocardium was indicated in 
experiments using animal models [36, 37]. Initial results from trials in human patients 
using autologous bone marrow cells were encouraging improvements in cardiac function 
that were only temporary [38–40]. In light of this enormous clinical burden, strategies for 
prevention, molecular genetics and cell therapy for cardiac repair and regeneration have 
attracted the attention. Regenerative strategies have moved rapidly for clinical application 
to patients. With aims repair or replacement of dysfunctional substrate, results from various 
animal models of MI and cardiomyopathy suggest that therapy with adult bone marrow 
cells (BMCs) improves LV function and attenuate LV remodelling [41]. Moreover, because 
the basis for improved recovery is unlikely mediated by (re)muscularization of damaged 
myocardium, the need to evaluate cells capable of differentiating into contractile tissue has 
been emphasized.
Contractile restoration of myocardial scars remains a challenge with important clinical impli-
cations. A unique feature of the cardiac muscle is the presence of transverse lines responsible 
for the contraction force and velocity of propagation of the cardiac impulse. Soler-Botija et 
al. developed a bioactive implant of biodegradable elastomeric membranes that act as a scaf-
fold. These membranes filled with a self-assembling peptide hydrogel and cell with cardiac 
potential were fully vascularized with functional vessel and observed via echocardiography 
positive effects on global cardiac motility [42]. The results suggested, in this case, that the ben-
efits of biodegradable scaffolds were not only due to local reduction in scar size, but to a more 
general event [43, 44]. Recent experimental studies have failed to answer important aspects 
of cell therapy. Cell therapy has more safety, improved cardiac function, increased healing, 
vascular density and increased regional circulation [45]. However, the efficiency of delivery 
and retention is lower than expected, and the retention and survival of cells at sites of delivery 
has been limited [5, 46, 47].
4. Tissue regeneration: a biomimetic design
In native tissue, cell growth and structural development are supported by an ECM that con-
sistently assists in coordinating the contractility and maintenance of cardiac shape and size, as 
well as the function of cardiomyocytes. The common interactions and orchestrated information 
exchange between cells associated into precise temporal and spatial context are the system-
atic presentation of biomolecules from biomaterials able to send biomolecular signals. Further, 
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even the size, shape and mechanical properties of a cell may be essential to the proper presenta-
tion of these signals to elicit the appropriate response and build the devices to cells orchestral 
arrangement [24]. Tissues organics repair is an exciting therapeutic conceit in the field of tissue 
engineering and biomaterial engineering. In the cardiac repair area, the most challenging aim 
is the creation of an engineered heart muscle. Tissue engineering is a hybrid technological sci-
ence, in which overall approach combines biology with materials science and has concentrated 
its efforts on the development of biomedical devices compatible with the ECM of target tissue. 
Similar to the matrix, the scaffolds must be able to anchor the cells of the native tissue.
Biomimetic design has started innovation in design as well as pointed to ways of improving 
existing biological devices. A method for finding and using these ideas would make biomi-
metic innovation more accessible by use of biomaterials that mimics the cardiac ECM, or 
other tissues. Biomimetic design is that, fully or partially, imitates or to make remember any 
biological natural phenomenon include all levels of organization belonging to the biological 
phenomenon that wishes to mimic the health tissue [48].
The major challenge of biomimetic design and develop of 3D devices biologically compatible, 
highly porous with interconnected porous that favour the transport of both nutrients and 
metabolic products while providing the analogous function, and mechanical stability. These 
devices are so-called scaffolds [49, 50]. The scaffold manufacturing design should take into 
account its purpose and represent important components for tissue engineering; in any case, 
it must achieve structures exhibiting the aforementioned characteristics. In the architecture 
of scaffold used for tissue regeneration, the choice of biomaterial is of critical importance. 
The variety of processes used in the manufacture of scaffolds modifying the surface and bulk 
properties influences both the architectural and the similarity of the scaffold with the native 
organic tissues, and may actively provide bioactive cues to the residing cells for regulations 
of the activities [50, 51].
The ECM is made up collagen type I (80%) and collagen type III (10%). The collagen serves 
to maintain normal cardiac architecture by surrounding and bridging myocytes, which con-
sistently assist in coordinating the contractility and maintenance of cardiac shape and size as 
well as the function of the cardiomyocytes [52]. In order of importance, the aim of regenera-
tive medicine is the use of synthetic, natural or composites biomaterial scaffolds to replace or 
repair damaged tissues, which have been investigated as candidates for cardiac regeneration. 
These natural and composite scaffolds are modelled on the natural extracellular matrix, which 
is a porous hydrogel consisting of collagen, fibroin, chitosan, gelatine, fibrin glue, alginate, 
glycosaminoglycans associated with biocompatible synthetic co-polymers as poly(lactic-co-
glycolic acid), polycaprolactone, ePTFE, PET, PUs, titanium, stainless steel and gold silver. 
These scaffolds provide both biomechanical support and biochemical signals to cells, and 
provide a biodegradable physical environment so as to allow neo-vascularization and remod-
elling in response to developmental, physiological and pathological challenges during tissue 
dynamic process morphogenesis, homeostasis and the built of a new tissue, inhibit apoptosis 
and attenuate LV dilatation and disease progression. Implantation of a novel biodegradable 
polyester urethane urea (PEUU) patch onto a sub-acute myocardial infarction promoted con-
tractile phenotype smooth muscle tissue formation and improved cardiac remodelling and 
contractile function at the chronic stage [53].
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Synthetic or natural biomaterials application in cardiovascular tissue repair and regeneration 
has shown increasing potential as a tool for such procedures, due its properties favourable 
for implantation while eliciting minimal side effect. Somewhat ambiguous, the biomaterial 
needs biocompatible and must interact organically and synergistically with the healthy part 
of the organ in order to reconstruct a new and neo-vascularized tissue over the area damaged 
by ischemia [54–57].
Separating the synthetic biomaterials is a shadow in comparison with the functional capa-
bilities of natural biomaterials, especially the biopolymers. Synthetic biomaterials are 
constructed of polycaprolactone, polylactic acid, polyglicolid, metals (titanium, stainless 
steel, gold silver) or a composite, for example poly(L-lactic acid)/poly(ε-caprolactone)/
collagen to mimic the native microenvironment of the myocardium [5]. A nanoscale PLA-
co-poly(ε-caprolactone)/collagen biocomposite scaffold was used to culture and support 
isolated rabbit cardiomyocytes. The results showed that adult rabbit cardiomyocytes 
attached to the scaffold exhibited growth and cell organization comparable to that found 
in native myocardium [5]. The main benefits of synthetic materials are their strength and 
durability, although their biocompatibility tissues and surface properties, which are gen-
erally poor to achieve a favourable environment for cell attachment [58]. Toxicity is the 
outmost concern with synthetic materials, especially in the case of biodegradable materi-
als, which can release potentially harmful by-products of degradation into the body. The 
linear aliphatic polyesters as PGA, PLA, poly(lactide-coglycolide) (PLGA) degrade through 
hydrolysis and are the most used for tissue engineering [59].
Each of tissue in the body is uniquely optimized to its specific organ system and offers an 
innate biocompatibility. Autologous tissue, or tissue harvested from and used for the same 
patient, is the current best solution for its superior functionality and no immunogenicity, 
these tissue are called homograft’s a utopia in the cardiac regeneration. Main ECM materials 
such as collagens, hyaluronan, fibronectin, elastin, fibrillin and proteoglycans among others 
are natural biomaterials for damaged tissue to repair in and around the area. In cardiovas-
cular applications, bovine porcine and equine tissue sources are playing a prominent role in 
establishing and maintaining an ideal microenvironment for tissue regeneration [54, 60].
Although the self-regeneration capacity of adult myocardium is insufficient to prevent the 
progression towards heart failure after various insults. To deal with limitation, the strategy 
can transfer progenitor cells from healthy area to disease heart area through scaffold implan-
tation. The utility of this approach is called into question by human and murine studies 
showing that progenitor cell quantities are in fact normal or increased in diseased versus 
healthy hearts. Evidence supports the existence of endogenous cardiac renewal and repair 
mechanisms in adult mammalian hearts that could contribute to normal homeostasis and 
the responses to pathological insults [60–62]. Studies demonstrate there is some amount of 
cardiac turnover, both in healthy and injured tissues, and this subject is important on cardiac 
regeneration after IM [63], as it also occurs cardiac pressure overload and idiopathic dilated 
cardiomyopathy [49, 64]. Naqvi et al. reported that cardiac cell proliferation is highest in 
youth, but in an average healthy adult, the cardiomyocyte turnover rate is controversial [65]. 
In an average healthy adult, the cardiomyocyte turnover rate is controversial with reports 
predicting annual turnover rates to more than 50% [66, 67]. Even although, it has been pro-
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posed that limited cardiac regeneration mechanism is pathways of to protect the heart from 
developing cancer, in fact, primary cardiac tumours are extremely rare [68]. Methods have 
been questioned in studies where turnover is on the higher end, in the meantime, regenera-
tive biology will bring together basic scientists and clinicians, developmental biologists and 
engineers, compelling us to expand our understanding of cell biology in order to grow new 
tissues [69, 70].
Biomaterials that mimic the ECM are used as a feasible alternative to cellular and molecu-
lar therapy in the field of tissue engineering. Biomaterials can be delivered alone, or serve 
as a scaffold or carrier for cells or growth factors. Scaffolds carefully design to support 
cellular growing has been development with finally of make a propitious environment 
for cardiomyocyte renewal. The biomaterials having individual, purpose-specific cues that 
can stimulate cells to behave in a predictable manner and in a pre-determined time course 
would have tremendous benefit to tissue engineering. When cells adhere and grow on the 
polymers substrates, cells sense, interpret and integrate extracellular signals through elec-
trical connections between cardiomyocyte and surface of protein biomaterial and respond 
to them [27].
Cardiac scaffold is a therapeutic intervention with low cost and efficacy and has significantly 
improved patients’ quality of life and prolonged their longevity [71–74]. The scaffold must reduce 
local micro-environment hostility persist for a sufficient time period over injured area to facilitate 
native cell migration and integration with native tissue to be feasible for cardiac repair/remodelling.
Delivery of cells using biomaterials has been shown to be an effective approach to control car-
diac fibrosis [33]. Fibrosis is a dynamic process, at the molecular and cellular levels, changes 
are characterized by generation of ROS, and data suggest fibrogenesis is a result of the com-
plex interaction involving TGF-β, ET-1, Ang-II and PDGF. Notably, TGF-β plays important 
roles in other biological processes, including homeostasis and normal repair. Pirfenidone 
(multiple target) and Nintedanib (BIBF-1120) inhibit multiple tyrosine kinases, a broad anti-
inflammatory and anti-fibrotic effect and have an effect blocking TGF-β and Ang-II–induced 
fibrosis [21, 75, 76]. While a new tissue is growing, it may release anti-inflammatory factors to 
control inflammation thus indirectly controlling cardiac fibrosis, released angiogenic factors 
promote tissue vascularization and regeneration [16]. To control of cardiac fibrosis for long-
term, high rate of cell survival in the infarcted hearts, high nutrition, high oxygen environ-
ment and catabolites’ elimination it is a necessary condition.
4.1. Effect of acellular scaffold on ventricular function and cardiac remodelling
A human cardiac organoid injury model reveals innate regenerative potential [77]. Under 
normal conditions, the ECM provides structural support for the heart, acts as a reservoir 
for cytokines and growth factors and provides a connection with surrounding cells that is 
important for transmission of extracellular cues [27, 78]. Following pathologic stimulation, 
the ECM undergoes remodelling of its structural components and matricellular protein lev-
els, for example; fibroblasts are influenced by autocrine and paracrine signal, and they are 
responsible for secretion and regulation of the ECM.
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Myofibroblasts secret important ECM proteins including collagens, fibronectin, periostin, 
metalloproteinases and tissue inhibitors of metalloproteinases, which collectively regulate 
ECM components in the process of cardiac remodelling. The ECM plays a critical role in the 
maintenance of the functional myocardium as well as the regulation of the heart’s response to 
stress or injury [27, 78]. Intelligent scaffolds that mimic ECM have recently emerged as a way 
to elucidate the interaction of native ECM molecules with living cells, to further understand 
how the ECM regulates their environment. Tissue engineering will open new avenues to sup-
port regeneration of diseased or damaged tissue.
Study provides novel insight into the endogenous regenerative capacity of the immature 
human heart, which cannot be investigated in the in vivo setting and is consistent with aspects 
of neonatal heart regeneration observed in vivo: lack of fibrosis, lack of hypertrophy, high 
baseline proliferation rates and functional recovery after injury. This model of study there-
fore provides an opportunity to interrogate the molecular and cellular mechanism governing 
regeneration of immature human heart tissue [73, 77].
Attempts to repair the injured myocardium with endogenous regeneration require an orga-
nized participation from various cell types including cardiac myocytes and local and periph-
eral stem cells. It is naive to think that only one cell type can participate in this regenerative 
process and may actually limit therapeutic opportunities. In summary, these approaches 
appear to have a sufficient effect on their target, a few is known on the strategies and the tissue 
regeneration [63, 79]. To date, a human model of acute cardiac injury has not been achieved. 
Instead, most research into regeneration following cardiac injury has relied on the use of 
animal models. However, recent studies suggest that reactivation of neonatal cardiac regen-
erative pathways to drive cardiomyocyte proliferation in the adult heart may be possible. 
Porrelo et al. found in neonatal mice suggest that therapeutic strategies aimed at restoring the 
proliferative potential of adult mammalian cardiomyocyte will be an important component of 
attempts to reactivate the dormant regenerative capacity of the adult mammalian heart after 
MI [80]. Voges et al. reported that immature human heart tissue possesses an innate ability to 
regenerate following injury. In addition, myocytes possess an endogenous ability to recover 
contractile force following injury, which occurs independently of other infiltrating/resident 
cell types, and that immune cells are not required for functional recovery of immature heart 
tissue. Furthermore, the addition of monocytes in our studies did not have any impact on car-
diomyocyte proliferation. This study suggests that immature human heart muscle may pos-
sess an intrinsic ability to mount a regenerative response, which occurs even in the absence 
of inflammation and angiogenesis [77]. Other studies have emerged documenting complete 
functional recovery of newborn human hearts following MI [63, 67, 81–83].
Adult cardiac myocytes represent a highly specialized and structured cell type; therefore, 
it is not surprising that complex and often overlapping systems have evolved to regulate 
cardiomyocyte growth. Typically, adult cardiac myocytes do not re-enter the cell cycle when 
exposed to growth signals, and further increases in cardiac mass are achieved through an 
increase in cell size or hypertrophy [84]. Due to the absence of understanding and the poten-
tial of how the heart cells can be migrated from health tissue to necrosis area, an intervention 
has not yet been developed that can regenerate the damaged myocardium after an infarct. 
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However, several groups have described the presence of a progenitor or steam cell that can 
differentiate into cardiac myocytes [15, 36, 61, 74, 85]. Thus, evidence has accumulated over 
the past 20 years to demonstrate that there is some amount of cardiac turnover, both in healthy 
and injured tissues [63, 77], and this has prompted efforts to devise cardiomyocyte replace-
ment therapies by the promotion of endogenous regenerative process [60, 62]. Evidence from 
rodent [86], axolotls, newts, zebrafish [77] and human studies challenges the view of the heart 
as a terminally differentiated organ and unable to regenerate [67]. The ability of ECM bioma-
terials to stimulate robust endogenous cardiac regeneration without adding exogenous cells 
would avoid these issues, today more and more studies show that this utopia is not more the 
‘holy grail’ of heart regeneration. The direct reprogramming of non-muscle cells into cardio-
myocyte-like cells by infecting or treating the heart with defined factors has improved. This 
approach was reviewed by Sadahiro et al., quoted by Foglia et al. [74, 82, 87, 88] that shows 
evidences about cardiac regeneration without exogenous cells.
We believe that the structure and function of cardiac tissues are regulated by weak nanoscale 
signals provided by ECM, which are exerting control over the function of cells and tissues. 
Thus, in the design of scaffolds, it is important to evaluate the effects of dialysis at the cell-
biomaterial interface for the creation of truly biomimetic cardiac constructs that replicate the 
structural and functional aspects of ventricular organization in vivo.
4.2. Scaffolds
ECM was commonly viewed as a rather inert scaffold, merely providing structural support 
for the cells embedded in its environment. However, ECM plays a critical and crucial role in 
the maintenance of the myocardium function, it is now recognized that the ECM forms in fact 
a very dynamic and plastic milieu also to regulation of the heart’s response to stress and a 
wide variety of cellular events and [78, 89].
A principal goal of regenerative medicine is the use of scaffolds to replace or repair damaged 
tissues. The scaffolds are modelled on the natural extracellular matrix, which is a 3D porous 
hydrogel that provides both mechanical support and biochemical signals to cells. Microscopic 
and ultra-structural scaffold topography is the key for cellular homing and migration to the 
target tissue.
For the increasing interest in tissue engineering to create a device for human tissues and 
organs, innovative techniques have been developed to generate scaffolds that arrange and 
form micro-architecture mimicking physiological structures. Tissue engineering requires the 
ability to promote the production and accumulation of ECM component. Alternative therapies 
with biomimetic scaffold expand the option of adult patient care; efficient means for repair-
ing, reconstructing or regenerating damaged tissues reduce the need for scarce donor organs.
In the field of myocardial tissue engineering, many efforts by the scientific community are ded-
icated to identify materials possessing specific mechanical properties that play a pivotal role.
Cells, biomaterials, scaffolds and growth-stimulating signals are referred to as the tissue engineer-
ing triad. Scaffolds typically made of polymeric biomaterials represent important components for 
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tissue regeneration. They are biopersistent (6 or 8 weeks), biodegradable, provide the structural 
support for cell attachment and growth and subsequent for tissue development [50, 90]. The stiff-
ness of native heart tissue ranges from 10 to 20 kPa at early diastole and increases to 50 kPa at the 
end of diastole, which may shoot up 200 kPa or more in infarcted heart [5]. The bioengineered 
scaffold matches as closely as possible those of the heart ECM in terms of stiffness, since the scaf-
fold should be flexible enough to promote the contraction of the growing cells.
In the scaffolds, nanoscale features must be included that replicate some of the functions of 
the ECM. In many cases, control of cell alignment and growth direction is essential to obtain 
functional tissues. Scaffolds 3D are able to control the growing of the cells. Hydrogel scaffold 
with oriented channels has been used with some success [91]. An injectable myocardial matrix 
hydrogel, derived from decellularized porcine ventricular ECM increase endogenous cardio-
myocytes, preserves cardiac function and is shown to reduce negative LV remodelling in both 
rat and pig models when delivered weeks after MI [92, 93].
Biomaterial has shown increasing potential as a tool for such procedures, due to its proper-
ties favourable for implantation while eliciting minimal side effect. Somewhat ambiguous, 
the biomaterial needs biocompatibility to interact organically and synergistically with the 
healthy part of the organ in order to reconstruct channels by cell migration a new and neo-
vascularized tissue over the area damaged by ischemia. If designed appropriately, biomateri-
als scaffolds can be delivered through minimally invasive approaches and stimulate cardiac 
repair, while avoiding many of the complications associated with a living product.
Biomaterial scaffolds are expected to provide a compliant and highly hydrated environment, 
similar to soft tissues having high water contents, thus facilitating diffusion of nutrients and 
cellular waste. The diverse nature of the organic tissue architecture requires pores sized in 
specific ranges compatible to each tissue. Since the myocardial tissue is subjected to cyclical 
and constant deformation, thus scaffolds are requested to show elastomeric properties and 
possibly long-term elasticity. The dimensions of the cardiac scaffold pores must be compat-
ible with the size of the heart cell phenotype, and the porosity should be above 85%, with pore 
interconnectivity favouring cell attachment.
Lim et al. related that their results on poly(L-lactic acid)-polystyrene blends reveal that cell 
adhesion is affected by surface chemistry, topography, and wettability simultaneously and 
that nanotextured surfaces may be utilized in regulating cell adhesion [94]. Therefore, chemi-
cal and physical signals from biomaterial surfaces (chemistry, topography, charge, energy 
and wettability) are critical extracellular stimulators that have the potential to regulate cell 
behaviour. The ability to robustly and reproducibly generate uniformly controlled (both 
structurally and functionally) and precisely defined engineered cardiac tissue will likely be 
necessary for eventual therapeutic products. This makes fabrication of biomaterials for myo-
cardial tissue engineering an attractive strategy. An effective scaffold for myocardial repair is 
a critical unmet need, where combining elasticity and strength without compromising heart 
cell viability and contractility have proved challenging.
Bioengineered cardiac tissue constructs can be divided into two categories: scaffold-cell-
based and scaffold-free. A number of 3D devices have been fabricated from natural biological 
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materials, such as collagen, fibrinogen, elastin, hyaluronic acid, fibrin, alginate fibronectin, 
laminin, from naturally occurring ECM and also fibroin, chitosan, gelatine, fibrin glue, associ-
ated with biocompatible synthetic or decellularized heart matrix.
Collagen is the most prevalent extracellular component of the myocardium and has used as 
a matrix for studying myocardial electrophysiology and contraction. Collagen is the primary 
force-conducting component of the ECM coupling cells to their force environment [90]. Cardiac 
myocytes are attached by integrin at specific sites near the Z band to an interconnected colla-
gen network containing other mechanically and biologically active extracellular matrix (ECM) 
components, including glycoproteins, proteoglycans, growth factors, cytokines and proteases 
A key property of collagen hydrogel-based engineered heart muscle (EHM) is its contractile 
performance, which reproduces many, but not all, aspects of contractile performance in native 
myocardium [95]. Some of the ECM protein collagens contribute the major tensile strength 
and viscoelasticity. In tissues, cells are anchored in a stationary, 3D network of collagen in a 
highly characteristic spatial arrangement. This spatial order arises from vectoral deposition of 
matrix and its subsequent tractional organization by cells. Bhatnagar et al. have shown that 
P-15 (mimic the bioactivity of type I collagen) bearing matrices mimic the physiological inter-
actions of collagen with cells. For example, the interstitial collagens are subjected to a myriad 
of post-translational modifications, including covalent and non-covalent cross-linking, leading 
to haptotactic cell migration, activation of signalling pathways, induction of growth factors, 
cell differentiation, tissue remodelling and morphogenesis in vitro and in vivo. Up-regulation 
of collagen cross-linking because of excess LOX activities can change various cellular behav-
iours. The authors describe such scaffolds as collagen substitute matrices [90, 96–98].
The plateau phase of the time trace at later times of the coagulation process, the fibrinogen is 
cleaved and cross-linked by exposure to thrombin and clotting factor XIII to form an insoluble 
fibrin mesh that captures blood cells to form a blood clot stiffness via thrombosthenin pro-
tein. Fibrin meshes can also be used to capture any target cell for tissue engineering [53]. 
Fibrinogen can also be conjugated with polyethylene glycol (PEG) to generate scaffolds that 
covalently bind growth factors and other proteins [99].
Elastin is a major fibrous protein in the extracellular matrix of organs and tissues that exhibit 
stretch and recoil, such as vessel walls. The elastic property maintains heart’s structural and 
biological functions. After an MI, the loss of elastin is the main factor adversely affecting ECM 
remodelling of the infarcted heart. The restoration of the elastic properties of the infarct region 
can prevent ventricular dysfunction [54]. The elastic properties of tissues are essential to main-
tain their structural and biological functions. The lack of elastic recoil contributes to the thinning 
and expansion of the infarct region, which frequently progresses after a myocardial infarc-
tion and results in cardiac enlargement and cardiac failure with time [100]. When the tissue is 
stretched, the elastin molecule is elongated, and when the stretching force is released, the mol-
ecule returns to its more stable random-coil structure and maintains the organ structure [85]. 
Most cells, such as fibroblasts, endothelial cells and smooth muscle cells, synthesize and secrete 
glycoproteins to form a microfibrillar scaffold on top of which tropoelastins, the soluble precur-
sors of elastin. Restoration of the elastic properties of the infarct region can prevent progressive 
cardiac dilation and deterioration of ventricular function following an MI [101]. Expression of 
elastin in the myocardial scar may be able to change the composition of the extracellular matrix 
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of the infarct region, preserves the elasticity of the infarcted heart, stabilizes an infarct and pre-
serves ventricular function [100]. Many other molecules, though lower in quantity, function as 
essential components of the extracellular matrix in soft tissues. Besides their basic structures, 
biochemistry and physiology, their roles in disorders of soft tissues are discussed only briefly.
Fibrous protein, including as well as collagen and elastin the fibronectin, laminin, fibrillin and 
integrins get a multi-domain structure plays a role of ‘master organizer’ in matrix assembly as 
it forms a bridge between cell surface receptors. Then these proteins contribute to the struc-
ture of the ECM, and modulate cellular functions such as adhesion, differentiation, migration, 
stability of phenotype, and resistance towards apoptosis. Integrin also plays an essential role 
in the assembly of fibrillin-1 into a structured network [78, 89]. Fibulins are tightly connected 
with basement membranes, elastic fibres and other components of extracellular matrix and 
participate in formation of elastic fibres [83, 86].
Tenascins are ECM polymorphic glycoproteins found in many connective tissues in the body. 
Their expression is regulated by mechanical stress both during development and in adult-
hood [46]. Tenascins mediate both inflammatory and fibrotic processes to enable effective 
tissue repair and play roles in pathogenesis of Ehlers-Danlos, heart disease, and regeneration 
and recovery of muscle-tendinous tissue [46, 89]. Increased expression of thrombospondin 
and TGF-β activity was observed in fibrotic skin disorders such as keloids and scleroderma. 
Thrombospondin-5 is primarily present in the cartilage. High levels of Thrombospondin-5 
are present in fibrotic scars, it plays a role in vascular wall remodelling and has been found in 
atherosclerotic plaques as well [30].
On the other hand, the extracellular macromolecules, notably glycosaminoglycan, are impor-
tant mediators of angiogenesis. Hyaluronic acid (hyaluronan) is widely utilized as a biosyn-
thetic biomaterial because of its biocompatibility and diverse array of physiologic functions. 
In its natural setting, hyaluronan is the only non-sulphated glycosaminoglycan present in the 
ECM of vertebrates, it is the most abundant and one of more important glycosaminoglycan 
in the heart development, and there are indications of playing a role in epicardium develop-
ment [102]. The highly viscous aqueous solutions (1000× its weight in water) thus formed 
give hyaluronan unique physicochemical and biologic properties that preserve tissue hydra-
tion, regulate tissue permeability through steric. In the ECM of connective tissues, hyaluro-
nan forms a scaffold for binding other large glycosilaminoglicans and proteoglycans. Bernanke 
and Markwald showed that hyaluronan treatment of avian AV cushion explants resulted in an 
increase of mesenchymal cells invading a 3D collagen matrix [103]. Large hyaluronan molecules 
are space-filling polymers presenting regulatory as well as structural functions, while small 
hyaluronan fragments are involved in immune stimulation, angiogenesis and inflammation 
[104]. 2-iminothiolane-grafted hyaluronan hydrogel and sodium periodate oxidated hyaluro-
nan cross-linked with adipic acid dihydrazide hydrogel were implanted into rat adductor 
muscles. The degradation tests demonstrated that the hydrogel could maintain the gel matrix 
over 35 days, depending on the ADH concentration, while inducing low inflammation and 
dense blood vessel formation in the areas surrounding the implanted hydrogels [105, 106]. 
Hyaluronan-mediated angiogenic effect in vivo is related to its degradation products, which 
stimulate endothelial cell proliferation and migration [102, 107]. Consequently, hyaluronan 
plays important roles in maintaining tissue morphologic organization, preserving extracellular 
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space and transporting ions, solutes and nutrients. Along with ECM proteins, hyaluronan binds 
to specific cell surface receptors such as CD44 and RHAMM [108]. The resulting activation of 
intra-cellular signalling events leads to cartilage ECM stabilization. Despite the fact that studies 
in the avian and murine heart clearly show the importance for hyaluronan in heart develop-
ment, there are, to the best of our knowledge, no published studies that show that hyaluronan 
insufficiency is associated with congenital heart disease in the human.
Other biomaterials that have been used to engineer myocardial tissue equivalents include 
alginates, silk fibroin and gelatine. In addition, it seems essential that the exogenous matrix 
be replaced to prevent interference with tissue formation. Still, vascularization of the matrix 
occurs quickly in conjunction with the immune response to the presence of foreign materials.
Alginate is a natural polysaccharide characterized by long chains of α-L-glucoronic acid and 
β-D-mannuronic acid. Alginate is a versatile biocompound and can be obtained with rang of 
molecular weight (32–400 kDa) and has been utilized as a hydrogel for tissue engineering. 
Due to its biologically favourable properties including the ease of gelation and its biocom-
patibility, alginate-based hydrogels have been considered a particularly attractive material 
for the application in cardiac regeneration and valve replacement techniques [109]. Alginate 
scaffolds were demonstrated to be safe, biodegradable and feasible to provide a conductive 
environment to facilitate the 3D culturing of cardiac cells. Scaffold with Ca-alginate enables 
incorporation and retention of cells and proteins inside the hydrogel scaffold. After implan-
tation into the infarcted myocardium, the biograft stimulated intense neo-vascularization 
and attenuated LV dilatation and failure in experimental rats compared with controls [29, 
110]. Alginates possess several crucial properties, which make them suitable for use in car-
diac regeneration. The first is their ability to be dissolved in water to yield aqueous solutions 
with moderate viscosity, which is particularly important for formulating injectable mixtures 
for cardiac therapies. The second is their ability to form hydrogels in mild conditions, for 
example, by adding cationic polyetrolytes salt to an aqueous solution to form the ionically 
triggered gelation, which is chemo reversible. Another advantage property of alginates is 
possible to modulate degradation rates and mechanical stiffness by choice of the appropri-
ate cross-linking agents [29, 55, 109]. Ionically, cross-linked, high molecular weight alginate 
hydrogels degrade in an uncontrolled fashion due to the slow loss of cross-linking cations.
As mentioned previously, one of the limitations for the use of synthetic polymers such as 
scaffolds is its low biodegradation in biological medium. Ashton et al. describe an alternative 
approach to design degradable alginate hydrogels based on the enzymatic degradation of 
alginate polymers. They incorporate poly(lactide-coglycolide) (PLGA) microspheres loaded 
with the enzyme alginate-lyase (PLGA-AL) into alginate hydrogels; controlling the amount of 
incorporated enzyme, and its rate of release from the PLGA microspheres, enables the rate of 
enzymatic degradation of the alginate hydrogels to be tuned [111].
There are two main solid forms of alginate used in cardiac regeneration, namely, hydrogels and 
porous 3D scaffolds. The hydrogel can contain over 99% water trapped in the network of water-
insoluble polymer chains. Depending on the freezing regime, the hydrogels could become 3D 
scaffold with interconnected pores, up to 200 µm in diameter and 90% of matrix porosity [112]. 
The current application involving alginate for cardiac regeneration include ventricle restoration 
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by injecting cell-free alginate, treating myocardial infarction by injecting calcium-cross-linked 
sodium alginate solution, patches for cell transfer in cardiac regeneration [109]. The potential 
use of the different alginate hydrogels as pharmaceutical excipients has not yet been fully evalu-
ated but alginate is likely to make an important contribution in the development of polymeric 
delivery systems. The precise chemical degradation mechanism and approaches in the choice of 
alginate for drug deliveries was previously broadly reviewed [113]. Leor et al. have suggested 
that intra-myocardial injection of alginate induces neo-vascularization and improved LV func-
tion [28, 110]. Alginate-based biomaterials for the treatment of MI is entering the clinical trials 
stage, therefore understanding the mechanisms by which these therapies affect LV remodelling, 
cardiac function and cardiac electrophysiology becomes a pivotal issue.
Biocomposite 3D scaffold consisting of two or more polymeric blends is used in order to 
obtain scaffolds with desired functional and mechanical properties depending on their appli-
cations. It is obtained useful the properties of natural and synthetic biomaterial. One such 
an attempt of using copolymer as poly(l-lactic acid)-co-poly(ε-caprolactone) (PLACL), poly-
glycerol sebacate, polyethylene glycol, polyvinyl alcohol, silk fibroin and alginate, collagen, 
hyaluronic acid, laminin and others biopolymers, that contribute to mimic the ECM, for fabri-
cating biocomposite scaffolds for cardiac tissue engineering have been proven to exhibit suit-
able biodegradable and mechanical properties. Mukherjee et al. showed that the hydrophilic, 
biocompatible nanofibrous scaffolds made of PLACL/collagen blend provide superior attach-
ment and growth of adult cardiac cells favouring native myocardium-like alignment of newly 
seeded cardiac cells compared to purely synthetic PLACL counterparts [5]. Biomaterial and 
biocomposite’s scaffold have featured prominently in cardiac regenerative therapy and have 
been explored to nanofibres, 3D devices, nanoparticles and patches to enhanced cell delivery 
and, more recently, has been used as acellular therapy.
5. Cardiac patches: in situ tissue regeneration
If on one hand to create engineered muscle construct in bioreactor is fascinating, on the other 
hand, it faces significant difficulties, in particular constructing significant cardiac muscle from 
scaffold and cells in vitro, and poor graft survival. In this approach, acellular scaffolds are 
implanted on the damaged myocardium and after their vascularization, they create a friendly 
environment and space for the implanted cardiomyocytes. Bioactive molecules with collagen, 
fibrinogen, alginate, hyaluronan, integrin, fibronectin and laminin improve viability and sur-
vival and may enhance stem cell homing and self-repair [28]. There is accumulating evidence 
that the heart contains resident progenitor cells that can be induced to develop into cardiac mus-
cle and vascular tissue. These cardiac progenitors could be recruited to repair the infarcted myo-
cardium. The incompleteness of myocardial repair as executed by all endogenous mechanisms 
collectively, including whatever progenitors exist intrinsic and extrinsic to the heart. At the same 
time, the identification of these cells opens the tantalizing possibility that they might be coached 
in vivo to home within the damaged myocardium, subsequently promoting functional cardiac 
repair without the need of introducing exogenous cells [118]. With this approach, the biomaterial 
itself or its degradation/dissolution products are used to stimulate local tissue repair.
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Cardiac patches thought that the microenvironment and architecture provided by such a scaf-
fold can support cellular differentiation and organization, and prevent a form of programmed 
cell death that occurs in anchorage-dependent cells when they detach from the surrounding 
ECM [114, 115]. When cells are detached from the ECM, there is a loss of normal cell-matrix 
interactions, and they may undergo anoikis. Nonetheless, the major drawback with this method 
remains the inability to generate patches with sizable thickness due to diffusion limitations. 
The biomaterial surface plays a crucial role as it forms the interface between the scaffold (or 
cardiac patch) and the cells [58]. The cells once implanted inside the scaffold will help the body 
heal itself [28, 116]. In animal models for ischemic cardiomyopathy, a variety of biodegradable 
materials as interventional therapeutic strategies have been investigated, including epicardial 
patches with and without cellular constituents. This approach might provide an attractive alter-
native to cellular cardiomyoplasty or larger ventricular restraint devices for cardiac repair.
‘Plastic Compression’ technique to create a biomimetic cellular dense collagen is used as a scaf-
fold for bone engineering, demonstrating its potential in tissue engineering. Double multiple 
compressions of hydrated collagenous scaffolds may initially result in enhanced mechanical 
properties; nonetheless, the double compression process exerted a negative impact on the 
seeded cell survival [117]. This compression technique can be also combined with other bio-
material to create a patch of collagen hybrid to cardiac regeneration with acellular scaffold.
Dense collagen scaffolds were characterized in terms of gel contraction ratio, morphology, 
the viability of seeded cells and mechanical properties of the gel and an engineered cardiac 
patch out of compressed type I collagen that improves recovery of the heart after acute myo-
cardial infarction through several processes, independently from exogenous cells and other 
factors. The main mechanisms responsible for this effect include the mechanical support of 
the scaffold, facilitation of cell migration and angiogenesis, and partial preservation of the 
heart muscle cells within the lesion and the area beneath the patch. Further investigations on 
therapeutic factors and/or cells that can be seeded within the engineered patch can be used in 
a new clinical therapy for cardiac repair following severe heart injuries [26].
Cardiac repair using chitosan-hyaluronan/silk fibroin patches in a rat heart model with myo-
cardial infarctions was examined after 8 weeks of study. The patches significantly improved 
LV functions in MI hearts with markedly reducing the dilation of LVs, increasing the thickness 
of their walls and improving their fractional shortening (LVFS) in the CHS group.
6. Scientific overview
As a concept, tissue regeneration is intuitively attractive and challenger. For conditions char-
acterized by MI and HF, the basic principle is that non-viable myocardium may be regen-
erated or repaired by delivery of stem or progenitor cells, including the heart itself. The 
cardiomyocyte has been considered terminally differentiated, with the response to injury 
characterized by hypertrophy. Recent evidence increases the possibility that a natural system 
of myocyte repair exists. Although the concept of myocyte repair is straightforward in the-
ory, realizing the potential of therapeutic strategies based on this concept is extraordinarily 
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complex, and the magnitude of this task has been highlighted recently. The patches using 
new biomaterial composite have been improved LV function in MI hearts with markedly 
reducing the dilation of LVs, increasing the thickness of their walls and improving their frac-
tional shortening. Collagen matrices are some of the oldest and most well understood classes 
of biomaterials. We agree with Chan et al.’s early efforts to simply harness isolated ECM as a 
substrate for culturing cells have expanded into a wide range of techniques to capitalize on 
the protein’s unique properties to create biomimetic hydrogels with well-defined properties. 
These materials and the knowledge they generate are enabling the development of new cell 
and matrix-based therapies that will overcome the limitations of less biologically relevant 
biomaterials [50]. Cells internally synthesize, modify and assemble the alpha chains into a 
procollagen form, which is secreted to the extracellular space and then partially cleaved by 
specific enzymes to form the tropocollagen molecule. These nanoscale subunits further self-
assemble into fibrils and are covalently bound to each other in a staggered manner, giving 
collagen fibrils a distinctive banded pattern when viewed at high magnification. Serpooshan 
et al. in an approach about the effect of bioengineered acellular collagen patch on cardiac 
remodelling and ventricular function post-myocardial infarction, brilliantly confirmed that 
there is integration histological and immunostaining of the scaffold in the patch form with 
native cardiac cells including fibroblasts, smooth muscle cells, epicardial cells and immature 
cardiomyocytes [26]. In conclusion, biomaterials synthetic and/or natural can be selected to 
form a 3D scaffold with controlled porosity, in the dense or laminate form, to recruit and 
organize native cells to repair or to attenuate remodelling and improve heart function fol-
lowing myocardial infarction.
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